Table 2. Patient clinicopathological characteristics.

Clinicopathological feature		NO. (%)
Gender	male	67 (59)
	female	47 (41)
Age (years)	<60	72 (50)
	≥60	72 (50)
	median (years)	59
Gastrointestinal bleeding	yes	44 (39)
	no	70 (61)
Primary tumor site	stomach	73 (65)
	duodenum	5 (4)
	intestine	24 (21)
	colorectum	7 (6)
	intraperitoneally with unknown primary origin	5 (4)
Tumor number	single	110 (97)
	multiple	4 (3)
Primary tumor size	>10 cm	31 (27)
	5.1–10 cm	44 (39)
	0–5 cm	39 (34)
Mitotic index (per 50 HPFs)	>10	11 (10)
	6–10	20 (18)
	0–5	83 (72)
Surrounding tissue invasion	yes	24 (21)
	no	90 (79)
Tumor necrosis	yes	67 (59)
	no	47 (41)
Predominant cell type	spindle	88 (77)
	epithelioid	15 (13)
	mixed	11 (10)
Cellularity	high	57 (50)
	moderate	45 (39)
	paucicellular	12 (11)
Postoperative IM treatment	yes	21 (18)
	no	85 (75)
	non-standard*	8 (7)
AFIP-Miettinen criteria	very low risk	30 (26)
	low risk	23 (20)
	moderate risk△	16 (14)
	high risk▴	43 (38)
	insufficient data	2 (2)

^*8 patients stopped IM treatment at mean of 2.2 months due to severe adverse effects;

^△one case with double tumors upstaged from low-risk;

^▴two cases with double tumors upstaged from moderate-risk; IM, imatinib mesylate.